Group 1 - The core point of the article is that Innovent Biologics has entered into a strategic partnership with Eli Lilly to advance global research and development of innovative drugs in oncology and immunology, with potential financial benefits amounting to $88.5 billion [1][4]. - Innovent will receive an upfront payment of $350 million and could earn up to $8.5 billion in milestone payments, along with a share of net sales outside Greater China [1][4]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) is fully invested in innovative drug R&D companies and has shown strong performance, leading its peers since 2025 [1][4]. Group 2 - The ETF's index is characterized by high purity, elasticity, and sharpness, demonstrating strong offensive capabilities in the innovative drug rebound market [1][4]. - The top ten constituent stocks of the ETF account for over 73% of its weight, indicating a concentrated representation of the core strength in innovative drug development [1][4]. - The ETF has recorded varying returns over the past five years, with a notable increase of 66.32% in one of the periods analyzed [1][4].
88.5亿美元，信达生物七度牵手礼来！核爆级BD密集落地，港股通创新药机会来了？